Next Investors logo grey

Capilano all sweet says Morgans

Published 08-AUG-2016 16:49 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Shares in Capilano Honey (ASX: CZZ) slumped from the previous day’s close of $21.35 to $20.31 on Friday in response to the company’s announcement that it had recorded a net profit of $9.5 million for the 12 months to June 30, 2016.

While this represented year-on-year growth of 20.9% and was in line with management’s guidance and the expectations of analysts at Morgans CIMB, it would appear that shareholders were looking for an outperformance from a stock that took on market darling status after listing on the ASX in August 2013.

On the first day of trading, the company’s shares closed at $2.44 but by September 2015 they had increased nearly ten-fold to hit an all-time high of $23.72.

Prices are subject to fluctuation and investors should take a cautious approach to any investment decision in this stock and not base that decision solely on price movements.

Belinda Moore from Morgans CIMB was satisfied with the result as she held firm with fiscal 2017 forecasts while slightly upgrading estimates for 2018. Moore also increased her price target from $23.10 to $23.50, while maintaining an add recommendation, although these targets are no guarantee of coming to fruition.

The price target implies a PE multiple of 15.5 relative to Moore’s forecasts for fiscal 2018.

From an operational perspective the analysts sees the fortunes of Capilano’s new high margin ‘health honey’ and the Comvita joint-venture as key determinants of the company’s success in fiscal 2018.

Moore also is of the belief that the company should benefit from better seasonal conditions in fiscal 2018, but in the agricultural industry one can’t make such assumptions with any surety.

Capilano has a strong balance sheet, which was recently strengthened by the sale of the manuka beekeeping assets to the joint-venture for $9.2 million. This leaves the company well-positioned to execute on its strategy of transforming from a purchaser of honey and bee products from other enterprises to a vertically integrated group benefiting from strong supply chain management and the scope to penetrate emerging markets in medical and natural health.

Moore’s revised share price target implies a premium of 15.7% to Friday’s closing price, but there is no firm evidence to suggest that the company’s in line for a rerating. In fact, if Friday’s share price slide is indicative of broader market sentiment there could be more downside to come.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.